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Introduction
The immunopathogenesis of TRAPS is thought to centre
on activation of the innate immune system resulting in
episodic inflammation. The adaptive immune system,
Tregs and Th17 T cells, has not been studied in TRAPS.
Different anti-TNF agents have different clinical effects
on TRAPS i.e. etanercept has benefits but adalimumab
and infliximab may trigger flares of TRAPS. It has been
shown that different anti-TNF agents have differential
effects on regulatory T cells in rheumatoid arthritis i.e.
adalimumab but not etanercept induces peripheral Tregs
which have the ability to suppress Th17 cells. We consid-
ered whether Tregs and Th17 cells in TRAPS could
underpin differential response to biologicals.
Objectives
To investigate whether there are differences in the num-
bers of regulatory T cells and Th17 cells in TRAPS patients
compared to controls.
Methods
Regulatory T cells from 5 patients with C33Y mutation
TRAPS and 5 healthy controls were analysed by flow cyto-
metric analysis on fresh blood. Lymphocytes which were
CD4+/CD25 high were regarded as regulatory T cells.
Th17 cells were also analysed by flow cytometric method
involving cytoplasmic staining for IL17. Cells which were
CD3+/CD8-/IL17+ were regarded as Th17 cells.
Results
The TRAPS patients included 2 patients on anakinra, 1 on
etanercept, 1 on tocilizumab and 1 on canakinumab. The
mean number of CD4+/CD25high cells was 21.4 cells/µl
in TRAPS patients compared to 13.2 cells/ µl in controls.
Although TRAPS patients had higher numbers of CD25
high T cells, this did not reach statistical significance with
a P value of 0.107. The mean percentage of Th17 cells in
TRAPS patients was 1.92% compared to 1.72% in controls;
p value of 0.649. Due to small numbers, it was not possible
to comment on any differences between different biologi-
cal therapies.
Conclusion
Although CD4+/CD25high regulatory T cells appeared to
be higher in the TRAPS patients, this did not reach
statistical significance which could reflect small numbers
studied. There were no significant differences in Th17
cells between the 2 groups. We suggest a further study of
a larger group of patients using intracellular FoxP3 stain-
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